Vanda Pharmaceuticals (VNDA) Operating Income Growth (1y) (2011 - 2026)

Vanda Pharmaceuticals (VNDA) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -24.89%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 2,150.96%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 8.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 145.20%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Vanda Pharmaceuticals 310.98 Mn 108.67 Mn 48.56 Mn -22.41%

Historic Data

Download Data
DateValue
Mar 31, 2026 -22.41%
Dec 31, 2025 -292.58%
Sep 30, 2025 -184.40%
Jun 30, 2025 -279.49%
Mar 31, 2025 -344.27%
Dec 31, 2024 -44.90%
Sep 30, 2024 -83.49%
Jun 30, 2024 -253.89%
Mar 31, 2024 -560.83%
Dec 31, 2023 -207.01%
Sep 30, 2023 -253.40%
Jun 30, 2023 -182.84%
Mar 31, 2023 126.13%
Dec 31, 2022 -23.24%
Sep 30, 2022 -63.88%
Jun 30, 2022 -72.02%
Mar 31, 2022 -174.16%
Dec 31, 2021 -17.37%
Sep 30, 2021 39.74%
Jun 30, 2021 34.87%